Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology.
Previous studies showed that memantine inhibits tau hyperphosphorylation in vitro. In this study, phosphorylated tau (P-tau) and total tau (T-tau) were measured before and after 6 month treatment with memantine in 12 subjects ranging from normal cognition with subjective memory complaints, through mild cognitive impairment to mild Alzheimer's disease. Thirteen non-treated individuals served as controls. Treatment was associated with a reduction of P-tau in subjects with normal cognition. No treatment effects were seen among impaired individuals, suggesting that longer treatment time may be necessary to achieve biomarker effect in this group.
Glodzik
Lidia
L
Center for Brain Health, Department of Psychiatry, New York University School of Medicine, 145 East 32nd Street, 5th Floor, New York, NY10016, USA. Lidia.Glodzik-Sobanska@nyumc.org
De Santi
Susan
S
Rich
Kenneth E
KE
Brys
Miroslaw
M
Pirraglia
Elizabeth
E
Mistur
Rachel
R
Switalski
Remigiusz
R
Mosconi
Lisa
L
Sadowski
Martin
M
Zetterberg
Henrik
H
Blennow
Kaj
K
de Leon
Mony J
MJ
D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000473:pathology; D000978:Antiparkinson Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D015415:Biomarkers / Q000134:cerebrospinal fluid; D001921:Brain / Q000473:pathology*; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008559:Memantine / Q000494:pharmacology* / Q000627:therapeutic use*; D016874:Neurofibrillary Tangles / Q000473:pathology*; D009483:Neuropsychological Tests; D010766:Phosphorylation / Q000187:drug effects; D012720:Severity of Illness Index; D013129:Spinal Puncture; D016875:tau Proteins / Q000378:metabolism
D000978:Antiparkinson Agents; D015415:Biomarkers; D016875:tau Proteins; D008559:Memantine